Lisata Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Employees
- 25
- Market Cap
- -
- Website
- http://www.lisata.com
- Introduction
Lisata Therapeutics, Inc. is engaged in the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Its product, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to target and penetrate tumors. It also actuates thi...
LSTA1 Phase 1b/2a Continuous Infusion Trial in MPDAC
- Conditions
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Lisata Therapeutics, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT06592664
- Locations
- 🇺🇸
University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸University of Kansas Cancer Center, Westwood, Kansas, United States
🇺🇸Spartanburg Medical Center, Spartanburg, South Carolina, United States
A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-02-03
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Lisata Therapeutics, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT05712356
- Locations
- 🇪🇸
Hospital Universitario de Vinalopó, Elche, Alicante, Spain
🇪🇸Hospital Universitario de Jerez, Jerez De La Frontera, Cadiz, Spain
🇪🇸Start Madrid - Hospital Universitario HM Sanchinarro, Madrid, Spain
CLBS201 in Patients with Chronic Kidney Disease (CKD) and Type 2 Diabetes Mellitus (T2DM)
- First Posted Date
- 2021-08-04
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Lisata Therapeutics, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT04990427
- Locations
- 🇺🇸
Clinical Advancement Center, PLLC, San Antonio, Texas, United States
A Placebo-Controlled Trial of CLBS16 in Subjects With Coronary Microvascular Dysfunction
- Conditions
- Interventions
- First Posted Date
- 2020-11-04
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- Lisata Therapeutics, Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT04614467
- Locations
- 🇺🇸
University of Florida - College of Medicine/ div of Cardiovascular Medicine, Gainesville, Florida, United States
🇺🇸Mayo Clinic in Rochester, Rochester, Minnesota, United States
🇺🇸The Christ Hospital, Cincinnati, Ohio, United States
CLBS119 for Repair of COVID-19 Induced Pulmonary Damage
- First Posted Date
- 2020-08-21
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Lisata Therapeutics, Inc.
- Registration Number
- NCT04522817
- Locations
- 🇺🇸
NYU Langone Health, New York, New York, United States
CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-05-07
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Lisata Therapeutics, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT03517176
- Locations
- 🇦🇺
Alfred Hospital, Melbourne, Victoria, Australia
🇦🇺Queen Elizabeth Hospital, Woodville South, South Australia, Australia
🇦🇺St John of God Hospital, Subiaco, Western Australia, Australia
Safety and Potential Bioactivity of CLBS16 in Patients With Coronary Microvascular Dysfunction and Without Obstructive Coronary Artery Disease
- First Posted Date
- 2018-04-26
- Last Posted Date
- 2021-01-08
- Lead Sponsor
- Lisata Therapeutics, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT03508609
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Mayo Clinic in Rochester, Rochester, Minnesota, United States
Safety and Efficacy of CLBS03 in Adolescents With Recent Onset Type 1 Diabetes (The Sanford Project T-Rex Study)
- Conditions
- Interventions
- First Posted Date
- 2016-02-25
- Last Posted Date
- 2021-01-08
- Lead Sponsor
- Lisata Therapeutics, Inc.
- Target Recruit Count
- 113
- Registration Number
- NCT02691247
- Locations
- 🇺🇸
University of Miami, Diabetes Research Institute, Miami, Florida, United States
🇺🇸Indiana University, Indianapolis, Indiana, United States
🇺🇸Rady Children's Hospital, San Diego, California, United States
Study to Assess the Efficacy and Safety of CLBS12 in Patients with Critical Limb Ischemia (CLI)
- Conditions
- Interventions
- First Posted Date
- 2015-07-17
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Lisata Therapeutics, Inc.
- Target Recruit Count
- 33
- Registration Number
- NCT02501018
- Locations
- 🇯🇵
Oita Oka Hospital, Oita, Japan
🇯🇵Asahikawa Medical University Hospital - 1-1-1 Higashi-2jou, Midorigaoka, Asahikawa-shi, Japan
🇯🇵Shonan Kamakura General Hospital, Kamakura, Japan
Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma
- Conditions
- Interventions
- First Posted Date
- 2013-06-12
- Last Posted Date
- 2019-05-10
- Lead Sponsor
- Lisata Therapeutics, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT01875653